CDC Foundation, USA; Centers for Disease Control and Prevention, Global Immunization Division, Atlanta, USA.
ZIMSTAT, Zimbabwe.
Vaccine. 2022 Mar 31;40 Suppl 1(Suppl 1):A30-A37. doi: 10.1016/j.vaccine.2021.05.074. Epub 2021 Jun 16.
Zimbabwe introduced human papillomavirus (HPV) vaccine nationally in May 2018, targeting multiple cohorts (girls aged 10-14 years) through a school-based vaccination campaign. One year later, the second dose was administered to the multiple cohorts concurrently with the first dose given to a new single cohort of girls in grade 5. We conducted cross-sectional surveys among health workers, school personnel, and community members to assess feasibility of implementation, training, social mobilization, and community acceptability.
Thirty districts were selected proportional to the volume of the HPV vaccine doses delivered in 2018; two health facilities were randomly selected within each district. One health worker, school health coordinator, village health worker, and community leader were surveyed at each selected health facility and surrounding area during January-February 2020, using standard questionnaires. Descriptive analysis was completed across groups.
There were 221 interviews completed. Over 60% of health workers reported having enough staff to carry out vaccination sessions in schools while maintaining routine vaccination services in health facilities. All school health coordinators felt the HPV vaccine should be delivered in schools in the future. Knowledge of the correct target cohort eligibility decreased from 91% in 2018 to 50% in 2020 among health workers. Understanding of HPV infection and use of HPV vaccine for cervical cancer prevention was above 90% for all respondents. Forty-two percent of respondents reported hearing rumors about the HPV vaccine, primarily regarding infertility and safety.
Findings demonstrate the presence of highly knowledgeable staff at health facilities and schools, strong community acceptance, and a school-based HPV program considered feasible to implement in Zimbabwe. However, misunderstandings regarding target eligibility and rumors persist, which can impact vaccine uptake and coverage. Continued social mobilization efforts to maintain community demand and training on eligibility were recommended. Integration, partnerships, and resource mobilization are also needed to ensure program sustainability.
津巴布韦于 2018 年 5 月在全国范围内推出了人乳头瘤病毒(HPV)疫苗,通过学校疫苗接种运动针对多个年龄组(10-14 岁女孩)。一年后,第二剂疫苗与第一剂疫苗同时接种给五年级的新的单一年龄组女孩。我们对卫生工作者、学校人员和社区成员进行了横断面调查,以评估实施、培训、社会动员和社区可接受性的可行性。
根据 2018 年 HPV 疫苗接种量按比例选择了 30 个地区;每个地区内随机选择了 2 个卫生机构。2020 年 1 月至 2 月,在每个选定的卫生机构及其周边地区,对每个选定的卫生机构及其周边地区的 1 名卫生工作者、学校卫生协调员、乡村卫生工作者和社区领导进行了调查,使用标准问卷。对各群体进行了描述性分析。
共完成了 221 次访谈。超过 60%的卫生工作者报告说,有足够的工作人员在学校开展疫苗接种活动,同时维持卫生设施的常规疫苗接种服务。所有学校卫生协调员都认为未来应在学校接种 HPV 疫苗。2018 年,卫生工作者对正确的目标年龄组资格的了解从 91%下降到 2020 年的 50%。所有受访者对 HPV 感染的认识和 HPV 疫苗在宫颈癌预防中的应用都在 90%以上。42%的受访者报告听到了有关 HPV 疫苗的谣言,主要是关于不孕和安全性的谣言。
研究结果表明,卫生机构和学校的工作人员知识渊博,社区高度认可,基于学校的 HPV 计划在津巴布韦具有可行性。然而,关于目标资格的误解和谣言仍然存在,这可能会影响疫苗的接种率和覆盖率。建议继续开展社会动员工作,以保持社区需求,并对资格进行培训。还需要整合、合作和资源调动,以确保项目的可持续性。